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Abstract 17 
Predictive approaches such as virtual screening have been used in drug discovery with the 18 
objective of reducing developmental time and costs. Current machine learning and network-19 
based approaches have issues related to generalization, usability, or model interpretability, 20 
especially due to the complexity of target proteins’ structure/function, and bias in system 21 
training datasets. Here, we propose a new method “DRUIDom” (DRUg Interacting Domain 22 
prediction) to identify bio-interactions between drug candidate compounds and targets by 23 
utilizing the domain modularity of proteins, to overcome problems associated with current 24 
approaches. DRUIDom is composed of two methodological steps. First, ligands/compounds 25 
are statistically mapped to structural domains of their target proteins, with the aim of 26 
identifying their interactions. As such, other proteins containing the same mapped domain or 27 
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domain pair become new candidate targets for the corresponding compounds. Next, a 28 
million-scale dataset of small molecule compounds, including those mapped to domains in 29 
the previous step, are clustered based on their molecular similarities, and their domain 30 
associations are propagated to other compounds within the same clusters. Experimentally 31 
verified bioactivity data points, obtained from public databases, are meticulously filtered to 32 
construct datasets of active/interacting and inactive/non-interacting drug/compound – target 33 
pairs (~2.9M data points), and used as training data for calculating parameters of 34 
compound–domain mappings, which led to 27,032 high-confidence associations between 35 
250 domains and 8,165 compounds, and a finalized output of ~5 million new compound–36 
protein interactions. DRUIDom is experimentally validated by syntheses and bioactivity 37 
analyses of compounds predicted to target LIM-kinase proteins, which play critical roles in 38 
the regulation of cell motility, cell cycle progression, and differentiation through actin filament 39 
dynamics. We showed that LIMK-inhibitor-2 and its derivatives significantly block the cancer 40 
cell migration through inhibition of LIMK phosphorylation and the downstream protein cofilin. 41 
One of the derivative compounds (LIMKi-2d) was identified as a promising candidate due to 42 
its action on resistant Mahlavu liver cancer cells. The results demonstrated that DRUIDom 43 
can be exploited to identify drug candidate compounds for intended targets and to predict 44 
new target proteins based on the defined compound–domain relationships. Datasets, 45 
results, and the source code of DRUIDom are fully-available at: 46 
https://github.com/cansyl/DRUIDom. 47 
Author Summary 48 
Drug development comprises several interlinked steps from designing drug candidate 49 
molecules to running clinical trials, with the aim to bring a new drug to market. A critical yet 50 
costly and labor-intensive stage is drug discovery, in which drug candidate molecules that 51 
specifically interact with the intended biomolecular target (mostly proteins) are identified. 52 
Lately, data-centric computational methods have been proposed to aid experimental 53 
procedures in drug discovery. These methods have the ability to rapidly assess large 54 
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molecule libraries and reduce the time and cost of the process; however, most of them suffer 55 
from problems related to producing reliable biologically relevant results, preventing them 56 
from gaining real-world usage. Herein, we have developed a new method called DRUIDom 57 
(DRUg Interacting Domain prediction) to identify unknown interactions between drugs/drug 58 
candidate compounds and biological targets by utilizing the modular structure of proteins. 59 
For this, we identify the domains, i.e., the evolutionary and functional building blocks of 60 
proteins, where these potential drug compounds can bind, and utilize this information along 61 
with protein domain annotations to predict new drug targets. We have tested the biological 62 
relevance of DRUIDom on selected proteins that play critical roles in the progression of 63 
numerous types of cancer. Cell-based experimental results indicated that predicted inhibitors 64 
are effective even on drug-resistant cancer cells. Our results suggest DRUIDom produces 65 
novel and biologically relevant results that can be directly used in the early steps of the drug 66 
discovery process. 67 
 68 
1. Introduction 69 
Drug development is an expensive and lengthy process, the cost of developing a new drug 70 
in the USA has been estimated at about $1.8 billion and takes on average 13 years [1]. One 71 
of the major cost influences is the attrition rate of drug candidates in late-stage development 72 
due to unexpected side effects and toxicity problems, arising from previously unknown off-73 
target interactions [2]. Indeed, the identification of molecular interactions between drug 74 
compounds and the intended target biomolecule(s) is the key to understanding and 75 
generating improved molecular designs leading to greater specificity. In the last decades, 76 
systematic high throughput screening (HTS) of large collections of chemical compounds has 77 
been widely utilized with the purpose of efficient lead identification, as well as efficacy 78 
evaluation and toxicity assessment [3]. Despite its advantages over previous strategies, HTS 79 
is an expensive technique that can only be afforded by big pharma. Furthermore, 80 
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considering the combinations between millions of small molecule drug candidate compounds 81 
and thousands of potential protein targets, the combinatorial number of experiments is 82 
extremely high, which is not possible to experimentally evaluate. 83 
Over the last two decades, computational approaches have been developed with the 84 
objective of aiding experimental studies in drug discovery, defining a new field entitled 85 
"virtual screening" or "drug/compound – target protein interaction (DTI) prediction" [4-6]. 86 
Here, the aim is to predict unknown compound – target interactions with the construction 87 
and application of statistical models, using various types of molecular descriptors [7]. There 88 
are two distinct approaches to virtual screening. In the ligand-based approach, new chemical 89 
substances are predicted as binders of the intended target biomolecules. This is usually 90 
performed by calculating molecular similarities between the drug/compound that is known to 91 
interact with the intended protein and other chemical substances in the library, thus, 92 
returning the most similar ones as predictions via “guilt by association” [8]. Since the 93 
predicted ligands of a target are usually limited to the compounds that are highly similar to its 94 
known ligands, discovering new scaffolds is difficult through this approach. In structure-95 
based virtual screening methods, 3-D structural information of known ligand – receptor 96 
complexes are used to model the interactions and predict new DTIs with similar interactive 97 
properties [9]. Structure-based virtual screening is a costly process due to both highly 98 
intensive computational processes and challenges associated with obtaining 3-D structures 99 
of both protein and receptor-ligand complexes [2]. As a result, they are mostly limited to the 100 
well-characterized portion of the target protein space. New computational approaches have 101 
emerged to address these issues by adopting machine learning and/or network analysis 102 
techniques [10-14]. There are cases where the drug candidate compounds, first discovered 103 
by virtual screening, or via computer-aided drug discovery in general, became approved 104 
drugs [4,15]. 105 
DTI prediction methods usually require large training datasets (i.e., experimentally verified 106 
interaction information between compounds and proteins) to build accurate models. 107 
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Bioactivity databases such as PubChem [16] and ChEMBL [17] curate and publish in vitro 108 
and in vivo bioassays, in the form of compound – target bioactivity measurements, which are 109 
used by DTI predictors as training data. The open-access data presented in these resources 110 
are extremely valuable for the research community; however, it is still difficult to find data 111 
concerning less-studied targets, which prevents building predictive models for these less 112 
common targets. Besides, the information in these databases is typically incomplete, 113 
meaning that there are many unknown/undiscovered interactions for the compounds and the 114 
targets presented in these resources, an aspect that is especially critical for estimating the 115 
off-target effects of the drug candidate compounds. Nevertheless, computational predictions 116 
concerning both under-studied targets and never-before-targeted proteins is an important 117 
topic that may help researchers to assess the druggability of these proteins and develop 118 
new therapeutic approaches.  119 
Modelling interactions between compounds and proteins is a difficult task especially due to 120 
the fact that molecular interactions between proteins and compounds are complex, also, 121 
many proteins expressed by the human genome are yet to be structurally characterized. In 122 
this sense, it is critical to reduce the complexity to a level where the modelling is feasible, the 123 
required data is available at large scale, and the results produced are biologically relevant. 124 
Proteins have modular structures made up of functional building blocks called domains. 125 
Domains can fold, function, and evolve independently from the rest of the protein [18]. 126 
Protein regions that correspond to domains are evolutionarily highly conserved since 127 
mutations in these functionally critical regions may lead to adverse consequences for the 128 
organism. Once identified on the structures of characterized proteins, domains can be 129 
detected (i.e., predicted) on structurally uncharacterized proteins by constructing domain 130 
sequence profiles and by searching for these profiles on the amino acid sequences of 131 
uncharacterized proteins [19,20]. Thanks to this application, domain/family annotation 132 
coverage is considerably high on the documented protein sequence space in the UniProt 133 
Knowledgebase (UniProtKB), i.e., 96.7% for UniProtKB/Swiss-Prot and 81.3% for 134 
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UniProtKB/TrEMBL. A few literature studies have investigated the relationship between 135 
domains and small molecules within the perspective of drug discovery and repositioning. For 136 
instance, Li et al. characterized the experimentally known binding interactions between 137 
domains and small molecules using data from Protein Data Bank (PDB). Consequently, they 138 
constructed a drug-domain network and used this to interpret modules of similar ligands and 139 
domains [21]. Kruger et al. proposed a simple heuristic to map Pfam domains to small 140 
molecules using ChEMBL bioactivity data as the source. The authors investigated the 141 
structural relevance of the idea of mapping domains to Pfam profiles with statistical tests and 142 
concluded that their heuristic produced accurate results [22,23]. Similar approaches have 143 
been used to predict gene – phenotype associations [24] and domain – domain interactions 144 
[25,26]. In a recent study, Kobren and Singh identified interactions between Pfam 145 
family/domain entries and various types of ligands using PDB co-complex structures. Their 146 
system InteracDome, employs the positional correspondence between Pfam HMMs and 147 
amino acid sequences of the protein chains in PDB structures, together with known ligand-148 
binding regions on the same protein chains, to predict the interacting receptor-ligand pairs 149 
[27]. Despite generating highly accurate mappings, InteracDome's coverage is limited 150 
considering small molecule ligands due to its reliance on PDB co-complex structures. These 151 
studies laid the foundation for the idea of associating small molecule binding to protein 152 
domains but they have neither proposed a complete end-to-end prediction pipeline, nor 153 
leveraged the advantage of using large-scale experimental bioactivity data accumulated in 154 
public databases such as PubChem and ChEMBL. Consequently, there is a clear 155 
requirement for new computational DTI prediction methods/tools, capable of producing 156 
reliable and consistent results by using all available data in data resources to aid 157 
experimental procedures in the field of drug discovery and repositioning. 158 
In this study, we propose a new computational method called DRUIDom (DRUg Interacting 159 
Domain prediction) for the comprehensive prediction of interactions between drugs/drug-like 160 
compounds and target proteins to aid experimental and computational research in drug 161 
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discovery and repositioning. DRUIDom is based on associating compounds (i.e., small 162 
molecule ligands) with complementary protein domains. The assumption behind the 163 
mapping between domains and compounds is that, the binding region of the ligand is on the 164 
mapped structural domain(s). Consequently, it is highly probable that other proteins 165 
containing the mapped domain (or combination of domains) will possess the required 166 
structural properties to interact with the compound of interest. DRUIDom employs a 167 
supervised modelling approach, where the manually curated DTI information in ChEMBL 168 
and PubChem databases are used in combination with the protein sequence and annotation 169 
information in the UniProtKB [28] and the InterPro databases [20], for the construction of the 170 
predictive model. The resulting predictions cover compound and human target protein 171 
spaces recorded in the above-listed databases. In DRUIDom, we also evaluated compound 172 
to domain pair mappings, in order to account for the cases where multiple domains are 173 
required for the indented ligand interaction. 174 
Our principal focus here was developing a complete chemogenomics-based drug/compound 175 
– target protein interaction prediction system with a global perspective without focusing on 176 
specific target families. For this, we constructed a large source bioactivity dataset and 177 
applied a scoring-based heuristic to generate the compound – domain associations, which 178 
are then propagated to other drug-like compounds and potential target proteins in the 179 
massive chemogenomics space to produce DTI predictions at large scale. We believe this 180 
study will provide valuable information for estimating both novel on-target and off-target 181 
effects of drugs and drug candidate compounds. 182 
With the aim of validating DRUIDom, we selected the PI3K/AKT/mTOR signalling pathway 183 
for our experimental use-case study. PI3K/AKT/mTOR pathway is altered during the 184 
progression of various cancer types [29]. Therefore, it is therapeutically relevant to target 185 
this pathway. As such we analyzed interacting compound predictions of DRUIDom for 186 
PI3K/AKT/mTOR pathway proteins, out of which, we focused on LIMK1 and LIMK2 proteins 187 
and their new ligand predictions, as these proteins have been associated with several types 188 
8 
 
of cancer especially in terms of progression and metastasis [30-33]. To be used in the 189 
experimental study, we synthesized the original 4 compounds predicted to inhibit LIMKs, 190 
together with their novel derivatives. Bioactivities of the predicted small molecule 191 
compounds were analyzed on transformed normal cells and cancer cell lines. The results of 192 
these experimental assays, which are described in the following sections, validated the 193 
computational predictions and indicate potential novel inhibitors for LIMK1 and LIMK2 194 
proteins that can be further investigated for their anti-migratory effects. 195 
 196 
2. Results 197 
Our source/training dataset is composed of 2,869,943 drug/compound – target protein pair 198 
data points (1,637,599 actives and 1,232,344 inactives) between 1,033,581 compounds and 199 
3,644 target proteins. Using drug/compound – target associations contained in this dataset, 200 
we first mapped compounds to domains, then, we produced DTI predictions by propagating 201 
mappings to new compounds and new proteins (Figure 1). Detailed information about the 202 
methodological procedure is given under 4.2.1 of the Methods section. Below, we first 203 
explain the conducted data analysis together with its results (2.1), serving both as a guide to 204 
determine the mapping parameters/thresholds and as a predictive performance evaluation of 205 
DRUIDom. This is followed by the detailed analysis of compound – domain pair mappings in 206 
comparison to single domain mappings (2.2), large-scale production of new drug/compound 207 
– target protein interaction predictions (2.3), a validation use-case study on the 208 
hepatocellular carcinoma (HCC) disease (2.4) with the selection of relevant targets (i.e., 209 
LIMK kinases) via literature review (2.4.1), molecular docking of selected novel inhibitor 210 
predictions against LIMK proteins as an in silico validation (2.4.2), and the wet-lab in vitro 211 
analysis of LIMK inhibition with the treatment of predicted inhibitors via chemical syntheses 212 
and cell-based assays (2.4.3). 213 
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Figure 1. (a) The overall representation of the drug/compound – target protein interaction 214 
prediction approach used in DRUIDom; and (b) drug/compound – domain mapping 215 
procedure and its scoring over two representative (c1, c2) toy examples. 216 
2.1 Predictive Performance Analysis 217 
The performance of DRUIDom was measured over the success of the mappings between 218 
the compounds and domains, since compound – domain mappings are at the core of the 219 
whole predictive process. As the reference benchmark (i.e., performance test) dataset, 220 
experimentally identified binding between proteins and small molecule compounds (i.e., co-221 
complex structures) has been employed. For this, we used the InteracDome (the non-222 
redundant representable list - v0.3) mappings [27] as our reference (i.e., gold-standard / 223 
benchmark) dataset, and calculated the performance of our compound – domain mapping 224 
procedure, for arbitrarily selected mapping score threshold values. In the InteracDome 225 
representable non-redundant set, there are 15,593 high-quality mappings indicating the 226 
interactions between 2,375 Pfam family/domain entries and 1,522 drug-like small molecules. 227 
The main reason behind using InteracDome as the reference dataset for the performance 228 
analysis of DRUIDom was that their samples are reliable, as all of them are cases of 229 
physical binding obtained from PDB.  230 
To prepare the performance analysis dataset, we first extracted the intersecting domain 231 
entries and compounds between the InteracDome benchmark and our source bioactivity 232 
dataset, to carry out the performance analysis on the intersecting set. Out of the total 2,375 233 
Pfam family/domain entries in the InteracDome, a collection of 1,043 were included in the 234 
target proteins in our source dataset, and thus, constitute the intersecting domain set. Pfam-235 
InterPro entry relationships were used for the conversion from Pfam to InterPro. Two main 236 
contributing factors to the reduced intersecting domain set are, we only used domain type 237 
entries in InterPro (leaving family type entries out since there is no structural 238 
correspondence to family entries), whereas InteracDome included family type entries along 239 
with domains; and second, there were several Pfam entries without any correspondence in 240 
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InterPro and many InterPro entries without corresponding Pfam signatures. Out of a total of 241 
1,522 compounds in the non-redundant representable InteracDome dataset, a group of 242 
1,144 were included in our mappings, and thus, constitute the intersecting compounds set. 243 
The main reason for the numerical difference is that many of the ligands in the InteracDome 244 
were not drug-like small molecules; whereas, in our mappings, all of the ligands/compounds 245 
were drug-like, as they were obtained from ChEMBL and PubChem. Next, we extracted all 246 
compound – domain pairs in InteracDome that include the intersecting compounds and 247 
domains. Following the construction of the finalized benchmark dataset, we compared our 248 
compound – domain mappings constructed at different mapping score thresholds with the 249 
benchmark mappings, to observe what portion of the benchmark mappings can be retrieved. 250 
Thresholds were applied on the performance scores of our mappings, calculation of which 251 
are described in the Methods section 4.2.1. Thus, a threshold of 0.7 means all compound – 252 
domain mappings with a mapping score recall, precision, accuracy, and F1-score less than 253 
0.7 are discarded. At each threshold, if a compound – domain pair in the benchmark dataset 254 
is also retrieved in our mappings, it is counted as a true positive (TP). If a benchmark pair 255 
could not be retrieved in our mappings, it is counted as a false negative (FN). If a pair in our 256 
mappings could not be found in the benchmark dataset, it is counted as a false positive (FP). 257 
Finally, if a potential compound – domain pair could not be found both in our mappings and 258 
in the benchmark dataset, it is counted as a true negative (TN). 259 
Table 1 displays the results of the compound – domain mapping performance analysis. As 260 
shown, performance increases with the increasing mapping score thresholds; however, the 261 
coverage of the mappings, with respect to InteracDome, decreases simultaneously. This 262 
was expected since increasing the confidence thresholds steadily eliminates more and more 263 
compound – domain mappings from our set, but the remaining mappings are more reliable. 264 
The coverage can be considered low even with the lowest confidence score threshold (i.e., 265 
coverage for ligands: 31% and for domains: 16.5%) due to the fact that experimental data 266 
sources behind InteracDome and our mappings are different from each other (i.e., co-crystal 267 
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structures and measured assay-based bioactivities, respectively). Since the performance is 268 
calculated considering the intersecting compounds and domains at each score threshold, 269 
the performance gradually increases with the increasing threshold, in terms of all metrics. 270 
Both the ligand and domain coverage, at the score threshold (0.9) that yielded the highest 271 
performance, was around 1% of the InteracDome. 272 
Here, InteracDome represents an incomplete reference dataset, as a result, DRUIDom’s 273 
compound – domain mappings, which are not presented in the InteracDome dataset, are not 274 
necessarily false positives. In cases like this, it is important to focus on performance in terms 275 
of detecting known/true (positive) associations. Inspired from a few domain – domain 276 
interaction prediction studies [25, 26], we calculated the enrichment of reference compound 277 
– domain associations in highest-ranking DRUIDom mappings (accompanied with its 278 
statistical significance value) with respect to random mappings on the exact same domain 279 
and compound datasets. For this, we ranked DRUIDom mappings according to pre-280 
calculated MCC-based mapping scores. At each arbitrarily selected mapping score 281 
threshold, we calculated the number of InteracDome associations found in DRUIDom 282 
mappings, in comparison to the expected number of InteracDome associations to be 283 
retrieved by randomly selecting the same number of pairs. For calculating the enrichment 284 
scores and their statistical significance, we used the hypergeometric test, as described in 285 
section “4.3 Mapping Score and Performance Analysis Metrics”, equations 6 and 7. 286 
According to results, the highest enrichment scores (i.e., > 6) are achieved when the 287 
mapping score threshold is selected between 0.1 and 0.6, all of which are found to be 288 
statistically significant with p-values < 10-16 (Table 1). It is also indicated from enrichment 289 
results that, at very low and high mapping thresholds enrichment is low, thus, selecting 290 
these points may not be ideal. 291 
Considering the trade-off between coverage and performance, we selected the confidence 292 
threshold of 0.5, which provided an acceptable performance (i.e., accuracy: 0.95 and MCC: 293 
0.78) and an InteracDome coverage of compounds: ~5% and domains: ~6%. At this 294 
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mapping score threshold, our approach produced 27,032 mappings between 250 domains 295 
and 8,165 compounds/ligands. 296 
We also calculated coverage extension values at each mapping score threshold to indicate 297 
the numbers of new domains and compounds that have been included in DRUIDom 298 
mappings (which are not presented in the InteracDome mappings at all). Coverage 299 
extensions are given in terms of rates (percentages) calculated with respect to the total 300 
number of domains (i.e., 1,043) and compounds (i.e., 1,144) intersecting between DRUIDom 301 
and InteracDome mappings (e.g., in the case of score threshold: 0.5, DRUIDom has 302 
mappings for 250 unique domains, 50 of which is shared with InteracDome, and it has been 303 
previously calculated that the total number of intersecting domains between DRUIDom and 304 
InteracDome is 1,043, as a result, the domain coverage extension at this point is calculated 305 
as (250-50)/1043 = 0.192, in other words: 19.2%). Considering coverage extension values, 306 
our mappings enriched the InteracDome dataset by ~19% for domains and ~707% for 307 
compounds (at the selected score threshold of 0.5), which indicates the added value of our 308 
approach, especially in terms of mapping new ligands. In this study, all of the steps followed 309 
after this point were carried out using the mapping set generated with the score threshold of 310 
0.5. However, in order to allow users to select other threshold values, we have also shared a 311 
file in our data repository (https://github.com/cansyl/DRUIDom) that includes raw/non-filtered 312 
compound – domain mappings together with their mapping scores. 313 





















Performance analysis results 
Mappings Domains Compounds 
Classification Enrichment 




Score MCC Score 
p-
value 
0 3,245,943 1,018 215,432 31.0 16.5 66.6 18,814.9 163 3,235 116 9,414 0.58 0.05 0.74 0.09 0.11 2.195 6.05E-14 
0.1 1,872,420 894 193,538 23.8 15.9 61.9 16,901.7 120 453 68 5,362 0.64 0.21 0.91 0.32 0.33 6.533 5.11E-43 
0.2 548,679 759 95,934 15.7 13.2 57.0 8,372.6 96 170 36 2,328 0.73 0.36 0.92 0.48 0.48 6.979 2.18E-34 
0.3 143,332 590 36,887 10.5 9.9 46.1 3,214.5 87 82 10 1,127 0.9 0.51 0.93 0.65 0.65 6.758 7.32E-28 
0.4 36,112 299 13,408 6.5 7.8 22.1 1,164.2 80 54 4 787 0.95 0.6 0.94 0.73 0.73 6.451 1.02E-23 
*0.5 27,032 250 8,165 4.8 6.4 19.2 707.3 72 37 2 622 0.97 0.66 0.95 0.79 0.78 6.443 5.65E-21 
0.6 21,592 197 4,752 3.1 4.5 15.8 410.8 65 22 1 457 0.98 0.75 0.96 0.85 0.84 6.111 1.28E-17 
13 
 
0.7 17,207 115 2,476 2.2 3.2 8.8 213.2 55 9 0 215 1 0.86 0.97 0.92 0.91 4.359 7.50E-10 
0.8 6,846 93 1,155 1.3 1.8 7.6 99.1 36 3 0 81 1 0.92 0.98 0.96 0.94 3.077 0.00024 
0.9 2,783 70 372 1.2 1.0 5.6 31.5 21 1 0 38 1 0.95 0.98 0.98 0.96 2.727 0.01617 
1 174 54 119 0.8 0.0 4.4 10.4 0 0 0 0 - - - - - - 1 
* Given as % of InteracDome. 315 
**The selected mapping score threshold (shown in bold font). 316 
 317 
2.2 Domain pair to compound mappings 318 
Here, our aim was to observe if it would be possible to identify the cases where the 319 
presence of a single domain is not sufficient for the occurrence of the interaction with the 320 
intended compound, instead, an interface composed of multiple domains are required. Other 321 
possible explanations for the requirement of multiple domains would be the allosteric 322 
binding/regulation phenomenon [34]. To analyze this process, we generated compound – 323 
domain pair mappings using the procedure explained at the end of Methods section 4.2.1. 324 
For this procedure, we used the "bag of domains" approach where the order of the domains 325 
on the protein sequence was not taken into account and all possible pair combinations were 326 
then generated and tested. The reason for this evaluation is that domains that are quite far 327 
away from each other on the linear protein sequence can be located very close to each 328 
other upon folding of the protein. 329 
Following the procedure described in the Methods section 4.2.1 and the thresholding/filtering 330 
of mappings with the selected parameter values described in the Results section 2.1, 3,721 331 
mappings were obtained between 1,456 compounds and 270 domain pairs. Next, these 332 
pairs were compared with single domain pairings of the same compounds, in terms of the 333 
mapping performance scores (e.g., C1 – DxDy is compared to C1-Dx and C1-Dy where C1 334 
represents a compound and DxDy represents a domain pair composed of the domains: Dx 335 
and Dy), to observe if there is any performance improvement by mapping a pair instead of a 336 
single domain (which is expected to provide more specific/defined interaction properties). In 337 
most of the cases, the performance of the domain pair mapping was the same as the 338 
mapping of the same compound to one of the single domains presented in the 339 
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corresponding domain pair, which indicates that only a single domain is sufficient for the 340 
binding, and the other domain in the domain pair is just an extra (i.e., the second domain 341 
does not play a detectable role in the binding). We called these domain pair mappings 342 
"neutral domain pair associations". However, there were a few cases that domain pair 343 
mapping actually increased the association performance, namely "positive domain pair 344 
associations". To prepare the finalized compound – domain pair mapping set, all of the 345 
neutral associations were discarded, yielding only 22 positive associations between 10 346 
compounds and 12 domain pairs. Below, we investigated one example from positive domain 347 
pair associations as a case study. The experimental bioactivity results of the case study 348 
were obtained from the ChEMBL database (document link: 349 
https://www.ebi.ac.uk/chembl/document_report_card/CHEMBL3621091), which was 350 
previously curated from the study by England et al. where the authors investigated potent 351 
inhibitors for KDM protein subfamilies [35]. 352 
The compound with the ChEMBL id “CHEMBL3621867” (link: 353 
https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3621867) was mapped to a 354 
single InterPro domain record named: "JmjN domain" (id: IPR003349, description: domains 355 
frequently found in the jumonji family of transcription factors, link: 356 
https://www.ebi.ac.uk/interpro/entry/IPR003349) with the confusion matrix values TP:3, 357 
FN:0, FP:1 and TN:2 (recall:1.00, precision:0.75, accuracy:0.83, F1-core:0.86, and 358 
MCC:0.71), the false positive hit indicates that there is one protein that contains IPR003349 359 
(gene: KDM4E, protein: "Lysine-specific demethylase 4E" in human, UniProt protein 360 
accession: B2RXH2, link: https://www.uniprot.org/uniprot/B2RXH2), which was recorded to 361 
be inactive against CHEMBL3621867 in ChEMBL database with a bioactivity value of IC50 = 362 
79.4 µM (and thus reported as a false positive in our analysis since the above mentioned 363 
single domain mapping predicted B2RXH2 as a target of CHEMBL3621867). Similarly, the 364 
same compound (CHEMBL3621867) was mapped to another single InterPro domain record 365 
named: "Zinc finger, PHD-type" (id: IPR001965, description: a C4HC3 zinc-finger-like motif 366 
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found in nuclear proteins thought to be involved in chromatin-mediated transcriptional 367 
regulation, link: https://www.ebi.ac.uk/interpro/entry/IPR001965) with values TP:3, FN:0, 368 
FP:1 and TN:2 (recall:1.00, precision:0.75, accuracy:0.83, F1-core:0.86 and MCC:0.71), 369 
indicating that, again, there is one protein that contains IPR001965 (gene: KDM2A, protein: 370 
"Lysine-specific demethylase 2A" in human, UniProt protein accession: Q9Y2K7, link: 371 
https://www.uniprot.org/uniprot/Q9Y2K7), which was recorded to be inactive against 372 
CHEMBL3621867 in ChEMBL database with a bioactivity value of IC50 = 50.1 µM (and thus 373 
reported as a false positive in our analysis since the above mentioned single domain 374 
mapping would predict Q9Y2K7 as a target of CHEMBL3621867). However, the mapping 375 
between CHEMBL3621867 and the domain pair IPR003349-IPR001965 yielded an excellent 376 
mapping performance with metrics TP:3, FN:0, FP:0 and TN:3 (recall:1.00, precision:1.00, 377 
accuracy: 1.00, F1-core: 1.00 and MCC: 1.00), by eliminating the false positive target 378 
predictions of B2RXH2 and Q9Y2K7 for CHEMBL3621867. The domain pair IPR003349-379 
IPR001965 is presented in 3 reviewed human protein entries among 6 proteins with 380 
measured activities against CHEMBL3621867 (i.e., Lysine-specific demethylases 4C, 5C 381 
and 4A, genes: KDM4C, KDM5C, and KDM4A, UniProt protein accessions: Q9H3R0, 382 
P41229, and O75164), all of which were targets of the corresponding compound verified in 383 
their respective binding assays with bioactivities of IC50 = 7.9, 6.3 and 5.0 µM, respectively. 384 
The protein that was accurately predicted as inactive by both single domain and domain pair 385 
mappings (i.e., as a true negative) was "Lysine-specific demethylase 6B" (gene: KDM6B, 386 
UniProt protein accession: O15054), which neither possessed IPR003349 nor IPR001965. 387 
This target also received a bioactivity measurement of IC50 = 63.1 µM against 388 
CHEMBL3621867. The IPR003349 domain is annotated to 10 reviewed human protein 389 
entries in the UniProtKB/Swiss-Prot database, also, IPR001965 is annotated to 88 reviewed 390 
human protein entries. Whereas together, IPR003349 and IPR001965 are annotated to 7 391 
reviewed human protein entries. Due to sequence differences between KDM subfamily 392 
proteins (i.e., only 6 identical positions and 39 similar positions out of more than 1500 393 
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positions in the multiple sequence alignment of 6 KDM subfamily proteins), their domain 394 
annotations are different from each other, which is possibly reflected in their 3-D structure 395 
(although it is not possible to be sure without a crystal structure), and thus, the interaction 396 
with the corresponding compound (i.e., CHEMBL3621867).  397 
It is important to note that, proteins annotated with only one of the domains listed above (i.e., 398 
IPR003349 or IPR001965) are also targeted by CHEMBL3621867; however, corresponding 399 
IC50s are way beyond plausible bioactivity values accepted for potential drug candidates 400 
(i.e., < 10 µM). On the other hand, the presence of both domains on the target protein 401 
yielded IC50 values that are within the acceptable range. This predicted domain pair – 402 
compound mapping does not directly state a true physical binding between the mapped 403 
domain pair and the compound, it rather suggests a relationship between the two entities 404 
where the interaction is stronger in the cases with the presence of both domains. Thus, 405 
targeting KDM subfamily proteins containing both IPR003349 and IPR001965 with 406 
CHEMBL3621867 would have a higher chance of success in a drug discovery study. 407 
It is probable for Q9Y2K7 (KDM2A) protein to partially possess the IPR003349 domain at 408 
the N-terminal side. If this is the case, the InterProScan tool might not report the hit due to 409 
obtaining a low score under the default statistical cut-off value. To analyze the case, we 410 
locally aligned (using Smith-Waterman with default parameters of gap open:10, gap 411 
extend:0.5, and scoring matrix:BLOSUM62) the first 100 N-terminal residues of Q9Y2K7 412 
(KDM2A) and O75164 (KDM4A), which is reported to possess IPR003349 between the 413 
positions 13 and 56 according to InterPro 414 
(https://www.ebi.ac.uk/interpro/protein/UniProt/O75164/). The output alignment reported a 415 
statistically significant hit (with 53.6% similarity between two sequences along the alignment 416 
length of 28 residues) between KDM4A sequence positions 11 and 38, which roughly spans 417 
the half of the IPR003349 domain, indicating the partial existence of the domain on Q9Y2K7 418 
(KDM2A). Nevertheless, the partial existence of the domain may be the reason behind 419 
observing interaction with a rather high bioactivity value (i.e., IC50 = 50.1 µM).  It is not 420 
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possible for us to further comment on the physical binding as there is no co-crystal structure 421 
of a KDM subfamily protein with CHEMBL3621867. 422 
Besides single domains and domain pairs, it is also possible for some of the drug/compound 423 
– target interactions to require three or even more domains to be presented at the target 424 
protein. We could not account for these cases in DRUIDom since they dramatically increase 425 
the complexity of the analysis, as a result, we chose to omit the cases requiring more than 2 426 
domains. 427 
2.3 Predicting New Drug/Compound – Target Protein Interactions 428 
Drug/compound – target protein interaction predictions were generated by propagating the 429 
drug/compound – single domain (or domain pair) mappings to proteins and other 430 
compounds, using the procedure explained in Methods section 4.2.2. The crossing of new 431 
compounds and targets for each mapping led to a geometric increase in the number of 432 
associations/predictions. Finally, a simple post-processing filter was applied to predictions to 433 
remove the known/recorded drug/compound – target protein interactions from the prediction 434 
set. 435 
First, 3,672,076 novel interactions (between 8,158 compounds and 5,563 proteins) were 436 
generated with the propagation of single domains to proteins (i.e., 250 domains to 5,563 437 
proteins). Also, 631 novel interactions (between 9 compounds and 286 proteins) were 438 
produced with the propagation of domain pairs to proteins (i.e., 12 domain pairs to 286 439 
proteins). The low number of predictions with domain pairs was due to the elimination of the 440 
domain pair mappings that did not display a performance increase over the single domain 441 
mappings of the same compound. At this point, the merged prediction dataset contained 442 
3,672,220 novel interactions between 8,163 compounds and 5,563 proteins, after the 443 
removal of duplicates. The finalized prediction dataset was obtained following the 444 
propagation of the compounds in the previous prediction set to significantly similar 445 
compounds according to molecular similarity-based compound clusters, which yielded 446 
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5,050,841 novel interactions between 10,944 compounds and 5,461 proteins in the finalized 447 
prediction dataset, following the removal of known interactions. One observation here is that 448 
there was only a slight increase in the number of compounds (from 8,163 to 10,944) after 449 
the pairwise molecular similarity-based propagation, which can be explained by the strict 450 
Tanimoto threshold of 0.8, which only passes the most reliable predictions. 451 
With the aim of making this long list of predictions more accessible, we grouped them based 452 
on signaling and metabolic pathways, in which the corresponding target proteins take roles. 453 
We believe this pathway-based classification will be useful to researchers, especially for the 454 
cases where specific biological processes are to be targeted (rather than a predefined single 455 
protein). Out of 5,050,841 interaction predictions, 3,686,558 of them contain target proteins 456 
that are annotated to one or more than one of 212 KEGG [36] signaling and metabolic 457 
pathways. We extracted pathway-based prediction statistics, including the number of 458 
interactions, and the number of unique compounds and proteins, for each pathway (Table 459 
S1), which showed that olfactory transduction, neuroactive ligand-receptor interaction, and 460 
calcium signaling pathways have the highest number of predicted ligand interactions. 461 
These predictions can be potentially used in future drug discovery/repurposing studies. Both 462 
the whole and pathway-based grouped compound – target interaction prediction lists are 463 
made available in the GitHub repository of the study (https://github.com/cansyl/DRUIDom). 464 
As explained in the dataset construction section (4.1), we discarded bioactivity data points 465 
between 10 and 20 µM from our training dataset as these are neither considered to be active 466 
nor inactive with any certainty. Thus, with the aim of observing how many of the compound – 467 
target pairs that fall into this bioactivity range (in the current version -v29- of ChEMBL) are 468 
predicted to be active/interacting by DRUIDom, we searched for these pairs among our 469 
finalized compound – target interaction predictions. Out of the 178,089 unique compound – 470 
target pairs with reported bioactivities between 10 and 20 µM, 263 of them are predicted to 471 
be active/interacting by our method (i.e., 0.15% of them), which are given in Table S2. This 472 
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low number can be attributed to the fact that most of the compounds in bioactivity databases 473 
are presented in only one (or just a few) compound – target pairs, and since pairs that fall 474 
into the 10-to-20 µM range have been omitted from the training dataset of DRUIDom in the 475 
first place, their compounds are missing from predictions (if they are not re-included due to 476 
ligand similarity-based extension of mappings). This is supported by the following statistics; 477 
among these 178,089 pairs, there are 124,189 unique compounds, and only 1483 of them 478 
are presented in all DRUIDom predictions. It is also important to state that this is a favorable 479 
finding since it is not desirable to produce active/interacting predictions to pairs with 480 
ambiguous relationships in reality. In the dataset of compound – target pairs with 10-to-20 481 
µM bioactivities, pairs that are predicted to be active by DRUIDom have a slightly lower 482 
median activity value (14.1 µM), i.e., more bioactive with lower xC50 values, compared to 483 
pairs that are not predicted to be active (mean activity: 14.7 µM). 484 
2.4 Validation of Predicted Molecular Interactions 485 
2.4.1 Selection of Target Proteins 486 
For in vitro and in silico experimental validation, we focused on the hepatocellular carcinoma 487 
(HCC) (i.e., a sub-type of liver cancer), which is the fourth most deadly cancer in the world 488 
[37], and on the PI3K/AKT/mTOR signalling pathway, due to its critical role in various types 489 
of cancer and cancer cell stemness [29]. To select inhibitory compound predictions, we first 490 
checked our large-scale drug/compound – target interaction prediction dataset and found 491 
116 inhibitor predictions (Table S3) for 4 PI3K/AKT/mTOR signalling pathway genes/proteins 492 
(i.e., VEGFA, MDM2, LIMK1 and LIMK2). Out of these 4 genes, VEGFA and MDM2 are 493 
relatively well-studied effectors of liver cancer, and there are several drugs and drug 494 
candidates that are being studied in the context of targeting these proteins as reported in the 495 
literature (please see https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL1783 and 496 
https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL5023, for VEGFA and MDM2, 497 
respectively). However, it is not possible to state the same for LIM kinases. 498 
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Metastatic potential and the invasiveness of cancer cells is dependent on the regulation of 499 
cytoskeletal remodeling and cell migration. LIMK proteins (i.e., serine/threonine-protein 500 
kinases) play important roles in metastasis by phosphorylating cofilin proteins which are 501 
involved in the dynamic remodeling of actin filaments [30]. LIMKs are required for the 502 
collective invasion by taking roles in invadopodium formation and extracellular matrix 503 
degradation in cancer cells [38,39]. Guo et al. reported a critical increase in LIMK1 levels in 504 
HCC, compared to the normal liver tissue. They also showed that the proliferation and 505 
migration capacity of liver cancer cells are suppressed with the down regulation of LIMK1 506 
[40]. Another study reported that the inhibition of LIMK/cofilin pathway via PAK1 inhibition 507 
(i.e., an activator of LIMK), suppresses the growth of several HCC cell lines, which is 508 
accompanied by decreased tumor value in vivo, due to the enhancement of apoptosis in 509 
relation to the blocked NF-kB activation [41]. 510 
Recent studies have shown that LIMK inhibition is effective in terms of decreasing 511 
proliferative and metastatic features of various tumor cells [31]. It has also been reported 512 
that motility and invasion capacity of breast and prostate cancer cells (with overexpressed 513 
LIMK1) was attenuated when inhibitors of upstream LIMK regulators are administered [42]. 514 
In the light of this information, LIM kinases can be considered as suitable candidates to 515 
target cancer progression and metastasis. 516 
With the aim of evaluating the prognostic effects of LIMK1 and LIMK2, we performed a 517 
Kaplan-Meier survival analysis on liver cancer (HCC) RNA-seq data, collected from 364 518 
patients [43]. It is observed from the results that the high expression of LIMK1 is significantly 519 
associated with a lower survival rate in HCC patients (Figure S1a). The median survival rate 520 
was calculated as 71 months in patients with low LIMK1 expression; whereas, the mean was 521 
37.8 months in patients with high LIMK1 expression. On the other hand, we did not observe 522 
a clear association between the survival rate and LIMK2 gene expression levels (Figure 523 
S1b). To examine the documented functional and sequence-based similarities/differences 524 
between LIMK1 and LIMK2, we checked their domain annotations from the InterPro 525 
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database, and observed that these proteins have the exact same domain architecture (i.e., 526 
from N to C terminal: “IPR001781: Zinc finger, LIM-type” – “IPR001781: Zinc finger, LIM-527 
type” – “IPR001478: PDZ domain” – “IPR001245: Serine-threonine/tyrosine-protein kinase, 528 
catalytic domain”, detailed information can be obtained from: 529 
https://www.ebi.ac.uk/interpro/protein/reviewed/P53667 and 530 
https://www.ebi.ac.uk/interpro/protein/reviewed/P53671). A Needleman–Wunsch pairwise 531 
global sequence alignment between LIMK1 and LIMK2 (with default parameters; the scoring 532 
matrix:BLOSUM62, gap open:10, gap extend:0.5) showed that these proteins are 51.9% 533 
identical and 66.8% similar to each other, and non-similar positions are mainly concentrated 534 
around the N and C terminal ends (the full alignment output is given in Supplementary 535 
Material section 3). Based on these results, it can be stated that further research is required 536 
to analyze different aspects of LIMK1 and LIMK2 in various types of cancer. 537 
In the light of this information, we decided to target LIM kinases in the experimental 538 
validation part of this study, with the main focus on LIMK1. Among the large-scale 539 
drug/compound – target interaction predictions provided by DRUIDom, 4 compounds have 540 
been predicted as inhibitors of both LIMK1 and LIMK2 proteins. Structures of these 541 
compounds are given in Figure 2 together with their ChEMBL database identifiers and short 542 
names as used in this study. These compounds are associated with LIMKs over their 543 
“Serine-threonine/tyrosine-protein kinase, catalytic domain” (InterPro domain id: 544 
IPR001245). In addition, we designed, synthesized, and tested 4 novel derivatives of the 545 
compound: “LIMKi-2” (derivatives: LIMKi-2 to d in Figure 2), which is found to be the most 546 
active one among the originally predicted inhibitors (explained below).  547 
Figure 2. Structures, database identifiers, and 2-D representations of predicted LIMK 548 
inhibitory compounds (LIMKi-1, 1a, 2, and 3) and derivatives (LIMKi-2a, b, c, and d). 549 
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2.4.2 Molecular Docking of Novel LIMK Inhibitors 550 
For in silico validation of computationally predicted LIMK inhibitors, molecular docking 551 
analyses were conducted. LIMK proteins (LIMK1 and LIMK2) are serine/threonine kinases 552 
with multidomain structures including 2 LIM zinc-binding domains, 1 PDZ domain, and 1 553 
protein kinase domain. Multi-kinase inhibitor staurosporine and previously described LIMK 554 
inhibitor 9D8 have published crystal structures with the kinase domains of LIMK1 and LIMK2 555 
proteins. These molecules were used as reference for docking, i.e., docking-based binding 556 
free energy (ΔG) output of computationally predicted LIMK inhibitors are evaluated in 557 
comparison to the docking output of these native ligands. In addition to computationally 558 
predicted compounds (i.e., LIMKi-1, LIMKi-1a, LIMKi-2, and LIMKi-3), novel derivatives of 559 
LIMKi-2 (i.e., LIMKi-2a, LIMKi-2b, LIMKi-2c, and LIMKi-2d) were also docked against kinase 560 
domains of LIMK1 and LIMK2 proteins. AutoDock grid box parameters used in these 561 
analyses are displayed in Table 2a, and the docking results of each LIMK protein – 562 
compound combination are shown in Table 2b, which displays the lowest of the binding free 563 
energies calculated from several poses obtained either from rigid or flexible docking in 564 
AutoDock. All files and results of the docking analysis, including the ones for online 565 
MTiAutoDock and SwissDock docking runs, are available in the data repository of the study 566 
(https://github.com/cansyl/DRUIDom) and in Table S4, respectively. Docking results 567 
obtained from different tools are consistent with each other. Based on the results in Table 568 
2b; LIMKi-2, LIMKi-2d, and LIMKi-3 have binding free energy values close to that of the 569 
reference ligand staurosporine (“staurosporine” ΔG=-10.55 kcal/mol, Ki=18.47 nM; “9D8” 570 
ΔG=-12.38 kcal/mol, Ki=0.837 nM) for the LIMK1 protein, where the lower values indicate 571 
stronger interactions. As for the LIMK2 protein, binding free energy values for all ligands, 572 
except LIMKi-1 and LIMKi-1a, were around the generally accepted thresholds to assume a 573 
potential activity (i.e., -10 to -12 kcal/mol), which were close to the value of reference ligand 574 
9D8 (i.e., -12.38 kcal/mol). In Figure 3, the best poses of LIMKi-2 and LIMKi-3 dockings 575 
against kinase domain binding sites of LIMK proteins are visualized along with the docking 576 
of reference molecules. The results indicate computationally predicted LIMK inhibitors, 577 
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especially LIMKi-2 (including its derivatives) and LIMKi-3, could be promising candidate 578 
molecules for targeting LIM kinases. 579 
Table 2. (a) Grid box parameters for AutoDock in the molecular docking analysis; (b) 580 
molecular docking results of computationally predicted LIMK inhibitors and their derivatives 581 
against kinase domains of LIMK proteins in terms of binding free energy (ΔG) and inhibition 582 
constant (Ki) estimations at the best poses (selected with respect to lowest ΔG). 583 
(a) 584 




x, y, z centers 
LIMK1 rigid docking 60-60-40 0.375 14.878, 6.646, 34.402 
LIMK1 flexible docking 80-80-60 0.375 14.878, 6.646, 34.402 
LIMK2 rigid docking 60-60-40 0.375 25.016, -13.952, 17.984 
LIMK2 flexible docking 80-80-60 0.375 25.016, -13.952, 17.984 
(b) 585 
 ΔG (kcal/mol) Ki (nM) 
 LIMK1 LIMK2 LIMK1 LIMK2 
Native ligands* -10.55 -12.38 18.47 0.837 
LIMKi-1 -7.68 -9.9 2340 55.14 
LIMKi-1a -7.47 -9.34 3330 142.42 
LIMKi-2  -10.11 -12.07 38.73  1.43 
LIMKi-2a -9.74 -11.32 72.38 5.01 
LIMKi-2b -9.13 -11.01 203.95 8.52 
LIMKi-2c -9.67 -11.92 82.22 1.83 
LIMKi-2d -10.28 -12 28.94 1.61 
LIMKi-3  -10.03 -11.92 44.34 1.82 
*Native ligands correspond to small molecule compounds staurosporine and 9D8 for LIMK1 and 586 
LIMK2, respectively. 587 
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Figure 3. Visualization of the docked complex structures of (a) LIMK1 kinase domain in 588 
complex with the reference molecule staurosporine (green), LIMKi-2 (violet), and LIMKi-3 589 
(red), and (b) LIMK2 kinase domain in complex with the reference molecule 9D8 (dark 590 
cyan), LIMKi-2 (violet), and LIMKi-3 (red) at the selected best poses with lowest binding free 591 
energy (ΔG). Hydrogen bonds are displayed with dark blue lines. Gold and pink colors 592 
represent LIMK1 and LIMK2 protein residues interacting with the corresponding compounds. 593 
2.4.3 In vitro Experimental Analysis of LIMK Inhibition 594 
LIMKi Compounds have inhibitory effects on human cancer cells 595 
To address whether predicted inhibitors have cytotoxic effects on transformed normal 596 
human (HEK-238) and various epithelial cancer cell lines (e.g., MCF-7, HCT116, Huh7, and 597 
Mahlavu), cells were treated with LIMKi compounds with a concentration gradient of 40 µM 598 
to 2.5 µM for 72 hours. The resulting cytotoxic IC50 values are given in Table 3a. While there 599 
is no cytotoxicity observed on normal cells, LIMKi-2 and LIMKi-3 compounds display 600 
cytotoxic activities between 5.5-17.3 µM on cancer cells.  Since LIMKi-2 showed the most 601 
potential bioactivity, we synthesized four novel derivatives of LIMKi-2 and assessed their 602 
bioactivities on Huh7 and Mahlavu liver cancer cells. LIMKi-2 derivatives; 2c, 2d displayed 603 
cytotoxic activities on Huh7 and Mahlavu cells (~8µM and <20µM, respectively), while 604 
LIMKi-2a had no effect (Table 3b). 605 
Table 3. Cytotoxic bioactivities of LIMKi molecules on human cells: (a) LIMKi-1,3 606 
compounds (b) LIMKi-2 derivatives. 607 
(a) 608 
LIMKi molecules 
IC50 Values (µM) 
LIMKi-1 LIMKi-1a LIMKi-2 LIMKi-3 
HEK-293 (Transformed Normal Human 
Embryonic Kidney Cell Line) 
NI NI NI NI 
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MCF-7 (Breast Cancer Cell Line) NI NI 6.4 ± 1.0 5.5 ± 0.3 
HCT116 (Colon Cancer Cell Line) NI NI 5.6 ± 1.3 6.8 ± 1.2 
Huh7 (Liver Cancer Cell Line) NI NI 7.9 ± 0.7 9.4 ± 1.2 
Mahlavu (Liver Cancer Cell Line) NI NI 13.8 ± 0.8 17.7 ± 0.3 
(b) 609 
LIMKi-2 derivatives  IC50 Values (µM) 
LIMKi-2a LIMKi-2b LIMKi-2c LIMKi-2d 
Huh7 (Liver Cancer Cell Line) NI 28.4 ± 2.5  8.2 ± 1.4  7.06 ± 0.8 
Mahlavu (Liver Cancer Cell Line) NI 24.6 ± 1.0  15.9 ± 3.1 15.3 ± 1.3 
 610 
As stated above, phosphorylated LIMK proteins are involved in actin cytoskeleton dynamics 611 
through cofilin phosphorylation, hence we performed experiments on the migration and 612 
invasion properties of liver cancer cells in the presence of LIMK inhibitors. We focused on 613 
Huh7 and Mahlavu liver cancer cells for the rest of the study, because primary liver cancer 614 
(hepatocellular cancer, HCC) usually presents with multiple tumors within the liver and 615 
intrahepatic metastatic spread is a major problem for this cancer [44]. 616 
LIMKi compounds are effective in vitro by reducing the level of cofilin phosphorylation 617 
Cofilin is a downstream molecule and its function is regulated by LIMK. Hence, we assessed 618 
phospho-Cofilin protein levels in Huh7 and Mahlavu cells in the presence of LIMK inhibitors. 619 
Phosphorylation of cofilin by LIMKs is significantly reduced upon treatment with LIMK 620 
inhibitors in both Huh7 and Mahlavu cells except for LIMKi-1 and LIMKi-2d, respectively 621 
(Figure 4a, b). Mahlavu cells are reported to have a resistant phenotype due to PTEN tumor-622 
suppressive protein deficiency for migration [45]. Therefore, the differential response against 623 
LIMK inhibitors by well-differentiated Huh7 cells and poorly differentiated drug-resistant 624 
Mahlavu cells are as expected and allows us to better assess the dose-response of LIMK 625 
inhibitors.  626 
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The ratio of phosphorylated to non-phosphorylated Cofilin protein levels, together with LIMK 627 
protein phosphorylation was previously reported as an indication of the metastatic potential 628 
of a cell [30]. Therefore, we also checked the ratio of phospho- to total Cofilin levels for both 629 
Huh7 and Mahlavu cells (Figure 4a, b) and found that LIMK inhibitors decreased the 630 
phospho-Cofilin ratio significantly. These results may lead to the discovery of novel 631 
therapeutic agents against the metastatic capacity of hepatocellular carcinoma cancer cells. 632 
Figure 4. Phospho-Cofilin protein expression; (a) Huh7 and (b) Mahlavu cells were cultured 633 
with LIMK inhibitors (20 µM) for 48 hours and expression of active p-Cofilin and total Cofilin 634 
levels were assessed with western blot analysis. The bar graph indicates the relative 635 
intensity of p-Cofilin levels compared to untreated DMSO controls. The equal loading control 636 
was analyzed based on the total protein staining normalization protocol. The ratios of 637 
phospho- and total Cofilin levels for both Mahlavu and Huh7 cell lines were calculated. 638 
LIMK inhibitors significantly reduce migration and invasion of HCC cells in vitro  639 
LIMK/Cofilin/ADF cascade has been described as one of the major regulators for actin 640 
cytoskeleton dynamics and reorganization [46]. Bioactivities of LIMKi compounds were 641 
tested for their effects on the migration and invasion capacity of HCC cell lines by wound 642 
healing and real-time cell invasion Transwell assays, respectively. First, Huh7 cell migration 643 
was analyzed in the presence of predicted LIMK inhibitors 1, 1a, 2, and 3. Huh7 cells have 644 
less migration capability compared to Mahlavu cells, so Huh7 migration was only tested with 645 
the originally predicted molecules. LIMKi-2 and LIMKi-3 strongly reduced the migration (2% 646 
gap closure) of Huh7 cells when compared to DMSO controls (48% gap closure) within 10 647 
hours (Figure 5a).  Then LIMKi-1, LIMKi-1a, LIMKi-2, LIMKi-3 and LIMKi-2 derivatives were 648 
tested on the migration of Mahlavu cells. LIMKi-2 derivatives reduced the resistant Mahlavu 649 
cell migration by 2.6-3.7 folds when compared to DMSO controls (Figure 5b).  650 
We also tested the bioactivities of predicted compounds and their derivatives by real-time 651 
cell invasion for 48 hours on Huh7 and Mahlavu cells. Figure 6 indicates that LIMKi-2d was 652 
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the most significant compound in terms of reducing the invasion capacity of both Mahlavu 653 
and Huh7 cell lines after 12 hours of treatment and throughout 48 hours. LIMKi-2c also 654 
significantly reduced Huh7 cell invasion. 655 
Figure 5: Wound healing assay. In vitro “wound” was created by a straight-line scratch 656 
across the monolayer (a) Huh7, (b) Mahlavu cells. Then cells were treated with indicated 657 
concentrations of LIMKi compounds for 10 hours and % wound gap closures were 658 
calculated. Bar graphs represent percent-based wound healing for Huh7 and Mahlavu cell 659 
lines. 660 
Figure 6: Cell invasion assay. Average cell index values are normalized according to 661 
DMSO, which is represented by the horizontal dashed line for; (a) Huh7, and (b) Mahlavu 662 
cell lines, in the presence of LIMK inhibitors. The serum-free media containing 20 µM of 663 
each LIMKi compound were used and invasion progress of cells was monitored via 664 
xCelligence DP RTCA System (*: p-value < 0.05, ****: p-value < 0.0001). 665 
 666 
3. Discussion 667 
In this study, the main objective was to develop a computational method for predicting drug 668 
(or drug candidate compound) – target protein interactions with high confidence, for the 669 
purposes of improved drug discovery and repurposing. In DRUIDom, we assumed a data-670 
driven approach and used experimentally validated interactions at large scale to build and 671 
optimize our model. For this, we utilized ChEMBL and PubChem databases and carefully 672 
filtered the bioactivity data points to construct our source dataset of drug/compound – target 673 
protein interactions, which is one of the largest curated, high-quality experimental bioactivity 674 
datasets ever built, as far as we are aware (composed of 2,869,943 interaction data points 675 
between 3,644 target proteins and 1,033,581 compounds). This dataset is available in the 676 
data repository of the study (https://github.com/cansyl/DRUIDom) and can be used by 677 
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researchers working in the fields of drug discovery and repurposing, both as a training and 678 
benchmark dataset for the construction of new computational predictive models. 679 
The idea behind DRUIDom’s methodology is to identify the protein domains that are required 680 
for successful interaction, and propagating these associations to proteins that possess those 681 
same domains. Thus, it was critical to successfully separate compound – domain mappings 682 
that indicate a true relationship from incidences observed by chance. For this, we 683 
incorporated known/verified compound – target protein relations with undesired bioactivity 684 
levels (i.e., high xC50 values: > 20 µM) as "inactives" even though they also are interactors, 685 
along with "actives" (compound – target protein pars with the desired levels of bioactivity: 686 
xC50 < 10 µM), as two different datasets. This approach enabled us to score compound – 687 
domain mappings in terms of potential true-false positives and true-false negatives (as 688 
explained in the Methods section 4.2.1), and to identify interacting pairs with a potential to 689 
ultimately become new treatment options. 690 
One limitation of our data-centric methodological approach is penalizing a compound – 691 
domain mapping with a false negative count if one of the known active target proteins does 692 
not contain the mapped domain. It is known that a small molecule (or fragment) can be the 693 
ligand of different proteins and different domains, especially when the structural features of 694 
the corresponding binding sites are similar to each other. In such cases penalizing a 695 
mapping leads to the underestimation of its mapping score. In order to minimize this effect, 696 
we took the InterPro domain hierarchy into account while calculating the mapping scores. 697 
InterPro combines domains from the same functional family under distinct hierarchical trees. 698 
There are also significant similarities between the sequence profiles of domains from the 699 
same hierarchy. In DRUIDom, while scoring a mapping, we checked whether the known 700 
active and inactive target proteins of the intended compound possess domains from the 701 
same hierarchy. Therefore, we counted an active target protein containing a domain from 702 
the same hierarchy (but not the actual mapped domain) as a true positive (instead of false 703 
negative) and counted an inactive target protein containing a domain from the same 704 
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hierarchy as a false positive (instead of true negative). In this way, domain similarity has 705 
been incorporated in DRUIDom. However, there are also cases where a single compound 706 
binds to domains from completely different hierarchies. Our approach currently does not 707 
take these cases into account. 708 
During the parameter optimization and performance analyses of DRUIDom, it was important 709 
to make sure that there was no data leak from the benchmark test dataset to our training set. 710 
This condition has been automatically satisfied since the source of the mappings in the 711 
InteracDome benchmark dataset (i.e., PDB co-complex structures) and the source of the 712 
mappings in our training dataset (i.e., assay-based biological activity measurements 713 
obtained from ChEMBL and PubChem databases) are completely independent from each 714 
other. 715 
In our analysis, we observed that only a small portion of the InterPro domain entries appear 716 
in the finalized compound – domain mappings, with the total number of 250 domains, as 717 
opposed to 8,165 compounds, at the selected mapping score threshold (i.e., 0.5). The main 718 
reason behind this observation could arise from the data distribution in the source bioactivity 719 
dataset; i.e., members from the same protein superfamilies have been targeted in most of 720 
the experimental bioassays (e.g., kinases, GPCRs). The distribution of the number of 721 
compounds mapped to each domain reveals that the top ten domains constitute 56.7% of 722 
27,032 mappings in total (i.e. “IPR000719 - Protein kinase domain”, “IPR001245 - Serine-723 
threonine/tyrosine-protein kinase, catalytic domain”, “IPR017452 - GPCR, rhodopsin-like, 724 
7TM”, “IPR020635 - Tyrosine-protein kinase, catalytic domain”, “IPR028174 - Fibroblast 725 
growth factor receptor 1, catalytic domain”, “IPR030611 - Aurora kinase A”, “IPR034670 - 726 
Checkpoint kinase 1, catalytic domain”, “IPR035588 - Janus kinase 2, pseudokinase 727 
domain”, “IPR035589 - Janus kinase 2, catalytic domain”, “IPR039192 - Glycogen synthase 728 
kinase 3, catalytic domain”). Overall, eight out of ten of these domains belong to kinases. 729 
We examined the difference in target proteins between our source bioactivity dataset and 730 
the resulting predicted DTI dataset, to observe if it was possible to produce predictions for 731 
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under-studied proteins with the approach outlined in this study. The unique number of target 732 
proteins in our source bioactivity dataset is 3,644, whereas, this number is 5,563 for our 733 
finalized DTI prediction dataset, which indicates that there is a 52.7% increase in target 734 
proteins due to the domain-based association approach. We also checked the protein 735 
superfamily distribution of the targets in the original and the predicted interaction datasets, 736 
considering five main classes of proteins as enzymes, membrane receptors, ion channels, 737 
transcription factors, and others (i.e., a combination of transporters, epigenetic regulators, 738 
secreted proteins, other cytosolic proteins, other nuclear proteins, and other categories), 739 
according to the first level (L1) of ChEMBL protein classification 740 
(https://www.ebi.ac.uk/chembl/g/#browse/targets). For this, we compared the target protein 741 
family distribution in the original bioactivity dataset (i.e., 64% enzymes, 11% membrane 742 
receptors, 5% ion channels, 4% transcription factors, and 16% others) with our DTI 743 
prediction dataset (i.e., 50% enzymes, 25% membrane receptors, 7% ion channels, 8% 744 
transcription factors, and 10% others). Although dominating families in the source bioactivity 745 
dataset prevail in the predicted DTIs dataset, we were able to produce interacting compound 746 
predictions for a critically higher number of proteins from membrane receptor, ion channel, 747 
and transcription factor superfamilies with a 248%, 114%, and 238% increase, respectively. 748 
These results, again, demonstrate the effectiveness of the domain-based approach in 749 
predicting new target proteins. 750 
In this study, we aimed to validate our drug/compound – target protein interaction prediction 751 
method by targeting the PI3K/Akt/mTOR pathway by focusing on the predicted LIM kinase 752 
inhibitors. The importance of selecting LIMKs as targets comes from their unique kinase 753 
domains which have longer activation loops compared to many kinases, allowing the design 754 
of specific inhibitors against cancer invasion and metastasis [42]. Furthermore, LIMK1 755 
knockout was not embryonically lethal in mice making this protein a good candidate for drug 756 
design [47]. Another study showed that LIMK activity is beneficial for cancer cells in terms of 757 
coping with chemotherapeutics and ionizing radiation, which renders cells resistant to these 758 
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treatments [48-51]. Therefore, LIMKs are promising candidates due to their essential role in 759 
cytoskeletal remodeling leading to cell migration and invasion. Hence, the lack of cytotoxicity 760 
of our predicted compounds on normal transformed HEK-238 cells is in parallel with the 761 
above-mentioned cellular LIMK activities, which is prominent in cancer cells.  762 
For the validation study, we initially examined the binding properties of 4 originally predicted 763 
compounds (i.e., LIMKi-1, 1a, 2, and 3) by computational docking and comparing with the 764 
crystal structures of multi-kinase inhibitor staurosporine and previously identified LIMK ligand 765 
9D8 in complex with LIMK1 and LIMK2 proteins, respectively. LIMKi-2, its derivatives, and 766 
LIMKi-3 had the most significant binding energies. During the in vitro validation stage of the 767 
study, we performed bioactivity experiments on liver cancer cells because intrahepatic 768 
metastatic migration/invasion is a major problem for patient survival and the specific 769 
selection of treatment is dependent on the number of distinct cancer nodules within the 770 
organ [52]. Our observations from the docking analysis were further supported by 771 
cytotoxicity and migration/invasion experiments where LIMKi-2 was the most significant 772 
compound regarding its action on cancer cells. Our promising results with LIMKi-2 directed 773 
us to synthesize 4 novel derivatives of this compound (i.e., LIMKi-2a, b, c, and d). Among 774 
these derivative compounds, LIMKi-2c and LIMKi-2d displayed highly significant anti-775 
migratory and anti-invasive properties on liver cancer cells, together with strong docking 776 
binding affinities. The increased activity for LIMKi-2c and 2d is interesting and seems to 777 
indicate a favorable change in conformation due to the bromide substituent that twists the 778 
benzene ring against the thiadiazole and causes loss of co-planarity. Finally, our evaluation 779 
singled out the novel LIMKi-2d compound as a promising candidate therapeutic agent due to 780 
its action on mesenchymal Mahlavu cells which are highly aggressive in terms of drug 781 
resistance for cytotoxicity, motility, and migration [53].  782 
As future work, we plan to further develop our predictive approach by identifying 783 
associations between ligands and experimentally characterized protein structures (from 784 
Protein Data Bank) and high-quality structure models generated by cutting-edge structure 785 
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prediction methods [54,55]. Furthermore, we plan to extend our mappings to 786 
uncharacterized protein sequence signatures using sources such as Pfam’s domains of 787 
unknown function (DUFs) [56], and potentially functional regions detected by different 788 
computational approaches [57]. Additionally, we are going to integrate DRUIDom’s 789 
compound – domain and compound – target interaction predictions to our large-scale 790 
biological and biomedical data integration and representation system CROssBAR [58] with 791 
the aim of enriching the biological relationship-based information provided in this service 792 
(https://crossbar.kansil.org/). This way, users can easily browse pre-computed DRUIDom 793 
associations/predictions for their proteins of interest, on the fly, together with other types of 794 
biomolecular relationships provided in this system (i.e., genes/proteins to diseases, 795 
phenotypes, pathways/functions, drugs, in addition to PPIs). Finally, we plan to extend the 796 
work on LIMK inhibition with additional in vitro experiments and in vivo studies, with the 797 
ultimate aim of contributing to the development of new anti-cancer drugs. 798 
The computational drug/compound – target protein interaction prediction approach proposed 799 
in this study led to the identification of novel interactions, a selected subset of which were 800 
then validated by both in silico and in vitro experiments. Results of the cell-based validation 801 
experiments indicate DRUIDom has the ability to generate generalized predictions that are 802 
well-translated into higher organizational levels such as the cell. Also based on these 803 
results, it is possible to state that the approach proposed here is producing biologically 804 
relevant results that can be utilized in drug discovery and repurposing studies beyond 805 
PI3K/Akt/mTOR pathway and cancer, especially for pathological conditions where specific 806 
domain-based targeting may be critical, such as metabolic disorders. 807 
 808 
4. Methods 809 
In this section, we first explain employed procedures for dataset construction and data 810 
processing (4.1), then we provided details of the proposed DTI prediction system, DRUIDom 811 
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(4.2), which is followed by the definition of scoring functions (4.3), particulars of docking 812 
analyses (4.4), and finally, a short summary of chemical synthesis and in vitro experiment 813 
procedures (4.5), details of which are given in Supplementary Material sections 1 and 2. 814 
4.1 Data 815 
4.1.1 The bioactivity dataset 816 
Bioactivity data points, each of which indicates the experimentally verified interaction 817 
between a compound and a target biomolecule (i.e., protein), were downloaded from open-818 
access bioassay databases and divided into 2 classes as active (i.e., interacting) and 819 
inactive (i.e., non-interacting, or more precisely: “non-interacting at the desired level”) pairs. 820 
For the selection of active data points, we used a bioactivity value threshold of < 10 µM xC50 821 
(i.e., IC50 or equivalent). For inactives, we used a bioactivity value threshold of > 20 µM xC50. 822 
The data points between 10 and 20 µM were discarded, since their classification to either 823 
class was considered to be ambiguous. 824 
ChEMBL bioactivity database [17] and PubChem bioassay database [16] were used as the 825 
bioactivity data source. The bioactivity data was acquired from the ChEMBL database (v23) 826 
via SQL queries with specified parameters (i.e., assay type: binding, target type: single 827 
protein, taxon: metazoa, standard value:  < 10 µM for active/interacting pairs and > 20 µM 828 
for inactive/non-interacting pairs). We only selected the data points with a pChEMBL value, 829 
which corresponds to a calculated activity measure of half-maximal response 830 
concentration/potency/affinity (e.g., IC50, EC50, AC50, Ki, Kd, and potency) in the negative 831 
logarithmic scale. pChEMBL value of 5 is equal to an xC50 measurement of 10 µM. The 832 
presence of a pChEMBL value indicates that the data point has been checked by a curator. 833 
Following these filtering operations, there were still cases where multiple bioactivity values 834 
are reported between a particular compound and target (i.e., duplicates). We thus take the 835 
median bioactivity value into account to treat these cases, similar to previous studies [10]. 836 
After the elimination of duplicates, the final ChEMBL set contained 718,102 bioactivity data 837 
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points (627,353 actives and 90,749 inactives) between 3,533 target proteins and 467,658 838 
compounds. 839 
Due to the structural organization of the PubChem bioassay database, it was not 840 
straightforward to obtain a bioactivity dataset with desired properties. However, the 841 
developers of ExCAPE-DB solved this problem by extensively filtering and organizing 842 
PubChem bioactivity data (together with ChEMBL bioactivity data) and presented the results 843 
in a database [59]. ChEMBL v20 and the PubChem bioassay database (January 2016) are 844 
incorporated in ExCAPE. In our study, we incorporated PubChem bioactivities directly using 845 
the ExCAPE-DB. We discarded the PubChem data points where the actual bioactivity values 846 
were missing. These points could have been included using the assay outcome field, where 847 
each data point is already marked as either "active" or "inactive"; however, the test 848 
concentrations for these data points are not available, and it is probable that many of them 849 
do not obey the thresholds we determined. Following the elimination of data points with 850 
activity values between 10 and 20 µM, the final ExCAPE bioactivity dataset contained 851 
2,514,439 bioactivity values between 1,648 target proteins and 856,216 compounds. The 852 
reason behind the low number of target proteins compared to the ChEMBL dataset was that, 853 
in ExCAPE, only three organisms (i.e., human, mouse and rat) were included. Finally, 854 
ChEMBL v23 and ExCAPE datasets were merged to obtain the finalized bioactivity training 855 
dataset of the study. Since ExCAPE-DB incorporates ChEMBL data (from v20, which is an 856 
older version compared to the one we used) along with PubChem, many duplicates were 857 
added to our dataset following merging, which were eliminated by simply deleting repeat 858 
data points. Our finalized source bioactivity dataset contains 2,869,943 data points between 859 
3,644 target proteins and 1,033,581 compounds. 1,637,599 of these data points are in the 860 
actives class, and the remaining 1,232,344 are in the inactives class. The contradictions 861 
between active and inactive classes (i.e., compound – protein pairs that are listed both as 862 
active and inactive) are low, with only 1,574 cases (< 0.06%). 863 
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4.1.2 Target proteins and domains 864 
UniProt Knowledgebase -UniProtKB- v2019_01 [25] and InterPro v72 database [20] were 865 
employed as the source for target protein sequences and their domain annotations, 866 
respectively. InterPro integrates sequence signatures with functional significance from 13 867 
different manually curated and automated databases presenting functional and structural 868 
protein information. In InterPro, domain content, order and positions are pre-computed for 869 
each UniProtKB protein sequence using the InterProScan tool and the sequence 870 
profiles/HMMs and presented within a public dataset. We downloaded InterPro annotations 871 
for all of the target proteins in our dataset (i.e., 3,644) and eliminated the InterPro hits for 872 
non-domain type entries such as families and sites. This resulted in a total of 3,118 target 873 
proteins that had at least one InterPro domain hit, and thus, could be further used in our 874 
study. The average number of domains in these target proteins was 2.44. We also 875 
generated domain architectures, which can be defined as the linear arrangement of the 876 
domain hits on the protein sequence, for each multi-domain protein in our dataset. The 877 
domain architecture information is later used for mapping compounds to domain pairs, to 878 
account for the cases where multiple domains are required to be presented in the protein to 879 
have an interaction with the corresponding compound (the detailed procedure is described 880 
below). 881 
4.1.3 Compound representation and analysis 882 
Canonical SMILES notations were employed to represent the compounds. SMILES is a 883 
widely used system that defines the structures of chemical species as line notations [60]. 884 
SMILES representations of all compounds in our dataset were directly downloaded from 885 
ChEMBL and PubChem databases. Extended-Connectivity Fingerprints (ECFP4) [61] were 886 
generated for all compounds in our bioactivity dataset (i.e., 1,033,581), using SMILES as the 887 
input. Pairwise molecular similarities were measured between all compound pair 888 
combinations using the Tanimoto coefficient. Python RDKit module [62] and ChemFP library 889 
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[63] were employed to generate the fingerprints and to calculate the pairwise molecular 890 
similarities. 891 
4.2 DTI Prediction System 892 
The proposed prediction system contains two modules: compound – domain mapping 893 
(section 4.2.1) and the propagation of associations to other proteins and compounds 894 
(section 4.2.2). In the mapping module, small molecule drugs/compounds are 895 
probabilistically associated to single domains (or domain pairs) on target proteins, using 896 
experimentally verified compound – target interaction data in bioactivity data resources. In 897 
the second module, for each compound – domain pair, all proteins that contain the mapped 898 
domain and all compounds that are significantly similar to the mapped compound (in terms 899 
of molecular similarity) are crossed with each other to produce new drug/compound – target 900 
protein predictions.  901 
4.2.1 Compound – domain mapping 902 
Figure 1a displays the overall methodology within a schematic representation. In this 903 
example, a compound (Ci) and its target protein (P1) is reported to be interacting/bioactive 904 
(i.e., according to our definition of active; xC50 < 10 µM) in ChEMBL and/or PubChem. In this 905 
toy example, it has been identified from the InterPro database that P1 has one domain 906 
annotation (i.e., blue domain), on which the binding site/region of Ci (with the desired 907 
bioactivity) is assumed to reside. This makes other human proteins containing the blue 908 
domain (i.e., P2, P3, and P4) candidate targets for Ci and for other drug-like compounds that 909 
are significantly similar to Ci with Tanimoto similarity greater than or equal to 0.8 (i.e., Cx, Cy, 910 
and Cz). 911 
To quantize the association between a compound and a domain, we calculated mapping 912 
scores for each compound – domain combination, using verified active and inactive 913 
compound – target protein data points in our source ChEMBL + PubChem bioactivity 914 
dataset. For this, precision, recall, accuracy, F1-score, and Matthew’s correlation coefficient 915 
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(MCC) metrics are employed. MCC successfully measures the quality of binary 916 
classifications when there is a class imbalance [64], such as the case observed in our 917 
dataset. Here, binary classification is the decision for either the presence or absence of a 918 
bio-interaction between a compound and a domain. Definitions below are used to calculate 919 
mapping scores for an example compound (C1) and a domain (Dx): 920 
• True positives (TP) represent the number of proteins that contain domain Dx, where 921 
the reported bioactivity against compound C1 is within the actives portion (i.e., xC50 < 922 
10 µM), 923 
• False positives (FP) represent the number of proteins that contain domain Dx, where 924 
the reported bioactivity against compound C1 is within the inactives portion (i.e., xC50 > 925 
20 µM), 926 
• False negatives (FN) represent the number of proteins that do not contain domain Dx, 927 
where the reported bioactivity against compound C1 is within the actives portion (i.e., 928 
xC50 < 10 µM), 929 
• True negatives (TN) represent the number of proteins that do not contain domain Dx, 930 
where the reported bioactivity against compound C1 is within the inactives portion (i.e., 931 
xC50 > 20 µM). 932 
Mapping score metrics were calculated using the above-defined TP, FP, FN, and TN; with 933 
their formulations being provided in Methods section 4.3. For all the compound – domain 934 
mappings, high scores indicate reliable mappings and a high probability that the region of 935 
interaction lies on the mapped domain. In Figure 1b, the mapping procedure is shown for 2 936 
toy examples. Also, in Figure 1b, the number of TP, FP, FN, and TN for toy examples are 937 
given, together with the respective mapping scores (i.e., metrics). The first example 938 
corresponds to a case where there are 2 experimentally verified interacting (i.e., active) 939 
target proteins for compound C1. Both of these proteins contain the blue domain (i.e., a 940 
structural unit responsible for the interaction with C1.). C1 also has 3 inactive proteins (i.e., 941 
38 
 
targets with insufficient bioactivity), 2 of which contain the red domain and 1 contains the 942 
light green domain. With the selection of the domain with the maximum score, the blue 943 
domain is mapped to C1. A further example mapping case is presented for compound C2, 944 
where most of the known targets are multi-domain proteins. For C2, many of the targets 945 
contain the green domain, red domain, or both of them. Association scores for single 946 
domains and domain pairs revealed that the best score is achieved when green and red 947 
domains exist together. It is observed that the real-world cases can be much more 948 
complicated compared to the toy examples provided in Figure 1b, as one protein can be the 949 
target of multiple compounds and one compound can target multiple proteins. To be able to 950 
separate reliable mappings from the non-reliable ones we determined and applied mapping 951 
score thresholds using the metrics provided in section 4.3. The test applied to determine 952 
these thresholds is described (together with its results) in the Results section 2.1. 953 
With the purpose of increasing the reliability of the data in our verified bioactivity dataset, we 954 
directly eliminated the mappings to the compounds if the number of active and inactive 955 
targets is less than 3 (each). This filter was applied to eliminate the compounds with only a 956 
few data points, which could otherwise produce false high mapping scores. This application 957 
dramatically reduced the number of compounds in our source dataset from 1,033,581 to 958 
51,750. To be able to incorporate more data points, we generated a second dataset by 959 
combining the active and inactive targets of the compounds in clusters, which were 960 
significantly similar to each other in terms of molecular structure, and treated each cluster as 961 
an individual compound while calculating the mapping scores. To distribute the compounds 962 
in clusters we used pairwise molecular similarities via Tanimoto coefficient (over ECFP4 963 
fingerprints) with a threshold of 0.7, which was above the previously applied threshold to 964 
predict targets based on compound molecular similarities [65]. All compounds that were 965 
similar to each other with at least 0.7 Tanimoto similarity were placed in the same cluster. 966 
Clusters with less than 5 active and 5 inactive targets were directly eliminated to ensure 967 
reliability in terms of the number of data points. In this way, 202,238 clusters were generated 968 
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with compound overlaps in-between. This procedure should not be confused with compound 969 
similarity-based propagation of target protein associations, which is explained in section 970 
4.2.2 below. The mapping score calculation was carried out for all of the 51,750 individual 971 
compounds in our first dataset (i.e., single-compound-based mappings) and for 202,238 972 
clusters in our second dataset (i.e., compound-cluster-based mappings) against domains of 973 
their respective target proteins. For the compound-cluster-based analysis, the score 974 
obtained for each domain mapping was propagated to all compounds in the corresponding 975 
cluster. This resulted in a total of 3,487,239 raw compound – domain mappings for the 976 
cluster-based bioactivity dataset (i.e., compound-cluster-based mappings) and 449,294 raw 977 
mappings for the individual compound-based dataset (i.e., single-compound-based 978 
mappings). 979 
Figure 7 displays the histograms composed of bins of the total number of targets, the 980 
number of active targets, and the number of inactive targets (X-axis), for individual 981 
compounds (Figure 7a, b, c) and for compound clusters (Figure 7d, e, f). Y-axis represents 982 
the number of compounds or compound clusters in the log scale. As observed, there was a 983 
steady decrease in the number of compounds/clusters when the number of targets per 984 
compound/cluster was increased. There was also a clear difference between active and 985 
inactive target bins. Indeed, no individual compound or cluster with higher than 80 inactive 986 
targets was identified. The most probable reason for this is that negative results (i.e., non-987 
interactions) are not usually reported in the literature. The gain from using compound 988 
clusters was highlighted especially for active targets and for all targets (i.e., a vs. d and b vs. 989 
e) with the increase in the height of the bars for more than 50 targets (notice the scaling 990 
difference in the X-axis between the individual compound histograms and the compound 991 
cluster histograms). 992 
Figure 7. Log-scale histograms of the number of individual compounds and compound 993 
clusters (Y-axis) with the given number of target proteins (X-axis) in our source bioactivity 994 
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dataset; for individual compounds: (a) all targets, (b) active targets, (c) inactive targets; and 995 
for compound clusters: (d) all targets, (e) active targets, (f) inactive targets. 996 
A similar procedure was applied to map compounds to domain pairs. For this, all domain 997 
pair combinations were identified for each target protein in our source dataset, using the 998 
domain architecture information of the proteins extracted using the UniProt-DAAC method, 999 
which was described in our previous study [66]. All domain pairs were recorded as if they 1000 
were single domains and the mapping procedure explained above was applied to obtain 1001 
compound – domain pair mappings. This procedure yielded a total of 1,075,550 raw 1002 
individual compound – domain pair mappings and 9,343,130 raw compound cluster – 1003 
domain pair mappings. The high number (compared to single domain mappings) was due to 1004 
the elevated number of domain pair combinations, especially for large proteins. 1005 
Once the mapping score threshold had been selected (as explained in the Results section 1006 
2.1), all mappings below the threshold were discarded, and the remaining mappings 1007 
constituted the finalized mapping dataset. 1008 
4.2.2 Propagation of associations 1009 
The second module starts with the detection of pairwise similarities between all compounds 1010 
in our source dataset using molecular fingerprints. For this, Extended-Connectivity 1011 
Fingerprints (ECFP4) [61] were generated for all compounds in our bioactivity dataset (i.e., 1012 
1,033,581). The pairwise similarities were measured using the Tanimoto coefficient with a 1013 
threshold of 0.8 to signify significant similarities, which was even above the previously 1014 
applied Tanimoto thresholds to safely transfer target annotations between small molecule 1015 
compounds [65]. Briefly, domain associations that were produced in the previous step were 1016 
transferred to new compounds that are similar to the mapped compound with a Tanimoto 1017 
similarity value greater than or equal to 0.8. The idea behind this application was that 1018 
structurally similar molecules tend to have similar interactions, as assumed in conventional 1019 
ligand-based virtual screening [61]. 1020 
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Subsequently, all human protein records in the UniProtKB/Swiss-Prot database were 1021 
searched for the mapped domains and domain pairs, using the InterPro domain annotation 1022 
information. When a new protein was found to contain the domain in question, it was 1023 
associated with the corresponding compound. In this way, new candidate ligands were 1024 
predicted for both known targets and for new candidate target proteins that possess the 1025 
mapped domains or domain pairs (Figure 1a). 1026 
4.3 Mapping Score and Performance Analysis Metrics 1027 
Precision, recall, accuracy, F1-score, and Matthew’s correlation coefficient (MCC) metrics 1028 
are used for both the calculation of mappings scores (Methods section 4.2.1) and calculation 1029 
of the overall system performance (Results section 2.1). The formulation of these metrics 1030 
are as follows: 1031 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = 	 !"
!"#$"
																																																						       (1) 1032 
𝑅𝑒𝑐𝑎𝑙𝑙 = 	 !"
!"#$%
																																																								       (2) 1033 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 	 !"#!%
!"#$%#$"#$%
																																															       (3) 1034 
𝐹1 − 𝑆𝑐𝑜𝑟𝑒 = 	 &	×	")*+,-,./	×	0*+122
")*+,-,./#0*+122
																																								       (4) 1035 
𝑀𝐶𝐶 = 	 !"	×	!%3$"	×	$%
4(!"#$")	×	(!"#$%)	×	(!%#$")	×	(!%#$%)
																														       (5) 1036 
Definitions for TP (i.e., true positives), FN (i.e., false negatives), FP (i.e., false positives) and 1037 
TN (i.e., true negatives) in the context of mappings scores are given in the Method section 1038 
4.2.1. We also calculated the enrichment of reference/known compound – domain 1039 
associations in DRUIDom mappings at different mapping score cut-offs, as a means of 1040 
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performance evaluation. For the calculation of enrichment score and its statistical 1041 
significance, we used hypergeometric test for overrepresentation, as shown in equations 6 1042 















*+"! 																																																					(7) 1047 
     1048 
where Et is the enrichment score calculated at the mapping threshold score of t; mt 1049 
represents the number of compound – domain mappings retrieved by DRUIDom (at the 1050 
mapping threshold score of t) that are also found in reference/true associations list; nt 1051 
represents the total number of compound – domain mappings retrieved by DRUIDom (at the 1052 
mapping threshold score of t); Mt is the total number of reference/true compound – domain 1053 
associations when we limit our domain and compound lists to the ones left in the DRUIDom 1054 
mappings list at the mapping threshold score of t; and Nt represents the total number of 1055 
compound – domain pair combinations (i.e., all random combinations) when we limit our 1056 
domain and compound lists to the ones left in the DRUIDom mappings list at the mapping 1057 
threshold score of t. Pt represents the significance (p-value) of the enrichment at the mapping 1058 
threshold score of t. 1059 
4.4 Molecular Docking Experiments 1060 
For the molecular docking of predicted inhibitor compounds and their derivatives against 1061 
kinase domains of LIMK1 and LIMK2 proteins, the crystal structure of LIMK1 kinase domain 1062 
as a complex with staurosporine (PDB id: 3S95) and the crystal structure of LIMK2 kinase 1063 
domain complex with bound 9D8 (PDB id: 5NXD) were retrieved from RCSB PDB database 1064 
[67]. Then, the PDB files of both protein structures were loaded into AutoDockTools-1.5.6. 1065 
For both proteins, which are in the form of 2-chain homodimer structures, only the A chain 1066 
was retained for docking and preprocessed by deleting all heteroatoms, adding hydrogen 1067 
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atoms, computing Gasteiger charges, and merging non-polar hydrogens. The preprocessed 1068 
protein structures were saved as pdbqt files. For flexible docking, contact residues of LIMK1 1069 
and LIMK2 proteins were selected and saved as flexible pdbqt files, while the remaining 1070 
structures of the proteins were saved as rigid pdbqt files. 1071 
Full 3-D structures of compounds were downloaded from ZINC (v15) database [68] in sdf file 1072 
format and converted to PDB files by Open Babel file format converter [69]. Since the 1073 
derivative compounds (i.e., LIMKi-2a, LIMKi-2b, LIMKi-2c, LIMKi-2d) could not be found in 1074 
the ZINC database, compound 3-D structures (in the form of PDB files) were generated from 1075 
the SMILES representations of respective compounds using ChemAxon JChem software-1076 
based online tool at: http://pasilla.health.unm.edu/tomcat/biocomp/convert. Then, Gasteiger 1077 
charges were added, rotatable bonds and the root for the identification of a central atom 1078 
were detected for compound PDB structures, and they were saved as pdbqt files in 1079 
AutoDockTools. 1080 
Grid map files for both rigid and flexible dockings were generated by AutoGrid4 program 1081 
(AutoDock-4.2.6) [70] using protein and compound pdbqt files as inputs, and the X-Y-Z 1082 
coordinates for the grid search were defined by calculating the mean coordinates of the 1083 
reported interacting atoms of LIMK1 and LIMK2 proteins, which were retrieved from 1084 
PDBsum [71]. Grid box parameters for grid search were set as shown in Table 2a. In the 1085 
docking step, a genetic algorithm with default settings was used for parameter searching, 1086 
and the docking analysis of each compound – protein pair was carried out by using 1087 
AutoDock4 (v4.2.6) [70]. 1088 
As a second docking validation, the same analysis was also performed using MTiAutoDock 1089 
[72] and SwissDock [73] web services. Protein pdb files were given as an input to the 1090 
MTiAutoDock service together with the sdf formatted ligand structure files. List of residues 1091 
mode was selected for grid calculation and the contact residues of each protein were given 1092 
as input. MTiAutoDock service has automatically added the hydrogen atoms to the crystal 1093 
structure and executed the docking procedure using AutoDock 4.2.6. For SwissDock, blind 1094 
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docking was implemented using protein PDB files and ligand mol2 files as input. For all 1095 
docking analyses, different poses were evaluated via binding free energy calculations and 1096 
the one with the lowest energy was selected as the finalized result (i.e., the best pose). 1097 
UCSF Chimera software was used for the visualization of docking results. 1098 
4.5 Chemical Synthesis and in vitro Validation of the Predicted Inhibitors 1099 
DRUIDom predicted 4 compounds as inhibitors of LIMK1 and LIMK2 proteins, which have 1100 
been selected as targets of the validation use-case study. Structures, database identifiers, 1101 
and given names (by us) of these compounds (i.e., LIMKi-1, LIMKi-1a, LIMKi-2, LIMKi-3) are 1102 
displayed in Figure 2. We synthesized these molecules to be used in the cell-based assays. 1103 
Also, the structure of LIMKi-2 has been modified with the aim of building 4 new derivatives 1104 
with a potentially higher biological activity (i.e., shown in Figure 2 as LIMKi-2a, LIMKi-2b, 1105 
LIMKi-2c, LIMKi-2d), making a total of 8 molecules. Procedures used in the chemical 1106 
synthesis of these molecules and the methodological details of in vitro experimental 1107 
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Figure 1. (a) The overall representation of the drug/compound – target protein interaction 1317 
prediction approach used in DRUIDom; and (b) drug/compound – domain mapping 1318 




Figure 2. Structures, database identifiers, and 2-D representations of predicted LIMK 1321 
inhibitory compounds (LIMKi-1, 1a, 2, and 3) and derivatives (LIMKi-2a, b, c, and d). 1322 







Figure 3. Visualization of the docked complex structures of (a) LIMK1 kinase domain in 1328 
complex with the reference molecule staurosporine (green), LIMKi-2 (violet), and LIMKi-3 1329 
(red), and (b) LIMK2 kinase domain in complex with the reference molecule 9D8 (dark 1330 
cyan), LIMKi-2 (violet), and LIMKi-3 (red) at the best poses. Hydrogen bonds are displayed 1331 
with dark blue lines. Gold and pink colors represent LIMK1 and LIMK2 protein residues 1332 
interacting with the corresponding compounds. 1333 













Figure 4. Phospho-Cofilin protein expression; (a) Huh7 and (b) Mahlavu cells were cultured 1345 
with LIMK inhibitors (20 µM) for 48 hours and expression of active p-Cofilin and total Cofilin 1346 
levels were assessed with western blot analysis.  Bar graph indicates the relative intensity of 1347 
p-Cofilin levels compared to untreated DMSO controls. The equal loading control was 1348 
analyzed based on the total protein staining normalization protocol. The ratios of phospho- 1349 
and total Cofilin levels for both Mahlavu and Huh7 cell lines were calculated. 1350 
  1351 
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Figure 5: Wound healing assay. In vitro “wound” was created by a straight-line scratch 1385 
across the monolayer (a) Huh7, (b) Mahlavu cells. Then cells were treated with indicated 1386 
concentrations of LIMKi compounds for 10 hours and percent-based wound gap closures 1387 
were calculated. Bar graphs represent percent-based wound healing for Huh7 and Mahlavu 1388 
cell lines.   1389 
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(a)             (b) 1390 
 1391 
Figure 6: Cell invasion assay. Average cell index values are normalized according to 1392 
DMSO, which is represented by the horizontal gray dashed line; (a) Huh7, and (b) Mahlavu 1393 
cell lines, in the presence of LIMK inhibitors. The serum-free media containing 20 µM of 1394 
each LIMKi compound were used and invasion progress of cells was monitored via 1395 
xCelligence DP RTCA System (*: p-value < 0.05, ****: p-value < 0.0001, p-values were 1396 
calculated in comparison to DMSO before the normalization). 1397 









Figure 7. Log-scale histograms of the number of individual compounds and compound 1402 
clusters (Y-axis) with the given number of target proteins (X-axis) in our source bioactivity 1403 
dataset; for individual compounds: (a) all targets, (b) active targets, (c) inactive targets; for 1404 
compound clusters: (d) all targets, (e) active targets, (f) inactive targets. 1405 
